Clinical trial
A Phase I Topotecan Study in Subjects With Cancer and Impaired Renal Function
NCT00483860 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00483860 |
|---|---|
| Title | A Phase I Topotecan Study in Subjects With Cancer and Impaired Renal Function |
| Official title | A Phase I Study of Oral Topotecan in Subjects With Cancer and Impaired Renal Function |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Solid Tumours |
| Intervention type | Drug |
| Interventions | Topotecan |
| Enrollment | 59 |
| Start date | Jun 20, 2007 |
| Primary completion | Feb 6, 2012 |
| Completion | Feb 6, 2012 |
| First posted | Jun 7, 2007 |
| Last update posted | Nov 13, 2017 |
| Countries | Netherlands, South Korea, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: